Phase 3, randomized, open-label study of epcoritamab plus lenalidomide compared with rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma Meeting Abstract
| Authors: | Ozcan, M.; Kim, W. S.; Zhang, H.; Bouzani, M.; Nagy, Z.; Chuah, H.; Salles, G.; Jeng, E. E.; Huang, J.; Sacchi, M.; Jiang, Y.; Minson, A. |
| Abstract Title: | Phase 3, randomized, open-label study of epcoritamab plus lenalidomide compared with rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 45021 |
| Language: | English |
| ACCESSION: | WOS:001411188300047 |
| DOI: | 10.1182/blood-2024-198700 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
